Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 20/20 | 0.65 |
| ▸ | PDE2A | O00408 | 18/20 | 0.65 |
| ▸ | PDE6D | O43924 | 6/20 | 0.59 |
| ▸ | PDE6A | P16499 | 6/20 | 0.59 |
| ▸ | PDE6G | P18545 | 6/20 | 0.59 |
| ▸ | PDE6B | P35913 | 6/20 | 0.59 |
| ▸ | PDE6C | P51160 | 6/20 | 0.59 |
| ▸ | PDE6H | Q13956 | 6/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.57 |
| ▸ | PDE4A | P27815 | 2/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4113567 | 0.84 | PDE10A (0.68) | PDE10APDE2APDE3APDE4A | |
| SCHEMBL3320907 | 0.81 | PDE10A (0.76) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL13334783 | 0.81 | PDE10A (0.73) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL3326386 | 0.80 | PDE10A (0.70) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL3325546 | 0.79 | PDE10A (0.78) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL3320916 | 0.79 | PDE10A (0.73) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL3322537 | 0.79 | PDE10A (1.00) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL3319252 | 0.78 | PDE10A (0.69) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL3320182 | 0.78 | PDE10A (1.00) | PDE10APDE2APDE6DPDE6APDE6G | |
| SCHEMBL3320416 | 0.77 | PDE10A (0.63) | PDE10APDE2APDE6DPDE6APDE6G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | claimed |
| WO-2010054253-A1 | TRIAZINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES | BIOTIE THERAPIES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120762-A1 | Triazine derivatives as inhibitors of phosphodiesterases | PDE2A, PDE5A, PDE12 | PDE10A 13/4885PDE2A 1/4885PDE6D 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.